Raymond James resumed coverage of Regenxbio (RGNX) with an Outperform rating and $27 price target The firm expects the launch of Elevidys and ...
Shares of Sarepta (SRPT) are down this morning, potentially due to the latest FDA Adverse Event Reporting System update on Elevidys, which ...
The data showed reduced difficulties in standing, walking and running that were statistically significant, the company said.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback